Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer

A Phase I/II Study of Escalated-dose Short-course Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer

This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the morbidity and cancer control provided by a 4-week course of treatment will greatly influence future radiotherapy services for patients with localized prostate cancer.

This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the morbidity and cancer control provided by a 4-week course of treatment will greatly influence future radiotherapy services for patients with localized prostate cancer.

Inclusion Criteria:

• Stage T1 and T2 prostate cancer
• Prostate specific antigen (PSA)>=20 and Gleason score<=6
• PSA<=15 and Gleason score 7
• Signed informed consent

Exclusion Criteria:

• No hip prosthesis, pins or screws
• No previous pelvic radiotherapy
• No inflammatory bowel disease